### **Overview** SMS Pharmaceuticals Limited, established in 1990 and headquartered in Hyderabad, India, is a leading integrated manufacturer of **Active Pharmaceutical Ingredients (APIs)** and intermediates. Operating in over **75 countries**, the company has evolved from a single-product unit into a globally recognized, research-driven API powerhouse. It is listed on both the **NSE and BSE** and serves more than **800 clients**, including top multinational pharmaceutical companies such as Mylan, Lupin, and Cipla. SMS Pharma specializes in **high-value, complex APIs** across therapeutic segments including **anti-diabetic, anti-epileptic, anti-migraine, anti-retroviral (ARV), anti-inflammatory, and anti-ulcer** therapies. The company also produces **high-volume commodity APIs** like **Ibuprofen**, strategically balancing scale and margin. --- ### **Core Strengths** #### **1. Global Leadership in Key APIs** - **World’s largest manufacturer of Ranitidine API** (until regulatory changes). - **Asia’s largest automated, single-block Ibuprofen production unit** with a reactor capacity of **3,000 kiloliters** at its Vizag facility. - Global leadership in **anti-migraine triptans**, with **up to 100% market share** in countries like Mexico and Japan. - Holds **40% value share in Ranolazine** (joint venture with Chemo). #### **2. Vertically Integrated, Cost-Competitive Model** - **Backward integration completed** for key APIs (e.g., Sitagliptin, Tenofovir), reducing raw material dependency and enhancing supply chain security. - Over **80% of intermediates are produced in-house**, minimizing reliance on Chinese imports (now only 10–15%). - **Zero Liquid Discharge (ZLD)** in Hyderabad ensures environmental compliance and sustainability. - Proprietary green chemistry innovations, such as recycling methyl mercaptan into DMSO (award-winning), reduce waste and cost. #### **3. Strong R&D and Regulatory Capabilities** - **Dedicated R&D center** in Hyderabad with kilo labs, pilot plants (4,500L), and analytical facilities. - Employs **over 100 scientists** (including PhDs), with plans to **double the R&D team** within 2 years. - **Over 120 Drug Master Files (DMFs)** filed globally with USFDA, PMDA, EU, KFDA, and ANVISA. - **35+ process patents** protecting cost-efficient, differentiated manufacturing processes. - Recognized by the **Department of Scientific and Industrial Research (DSIR)**, Government of India. #### **4. Strategic Partnerships and Diversified Revenue Model** - **Joint Venture (JV) with Chemo Iberica S.A. (Spain)**: Co-develops and commercializes APIs; Chemo handles sales in Europe, while SMS retains subcontinental rights. - Commercialized Ranolazine, Perampanel, Gliptins, and Flozins. - JV products contribute significantly to revenue and profitability. - **VKT Pharma (Associate Company)**: Vertically integrates downstream into **formulations**; has **USFDA-approved ANDAs** and contributes meaningfully to profitability. - Offers **CDMO/CRAMS services** to global pharma partners, serving as an **alternative manufacturing hub**. --- ### **Manufacturing & Capacity** - **Total react capacity: 3,120 KL** - **Vizag facility**: 3,000 KL — Multipurpose plant with Asia’s largest ibuprofen block (targeting **1,000 MT/month**, currently operating at ~500 MT/month). - **Hyderabad facility**: 120 KL — Focuses on **high-margin, niche APIs** like Tadalafil, Sumatriptan, and Itraconazole. - Both facilities have passed **multiple USFDA, EU-GMP, and WHO inspections**. - **Unit VII (Vizag)**: WHO-prequalified — strengthens ARV API exports. --- ### **Financial and Operational Performance (FY25 – Q2FY26)** - **Q2 FY26 PAT up 80% YoY** — driven by strong demand, market share gains, and margin expansion. - **FY25 PAT grew 39% YoY**, with EBITDA nearly doubling and strong top-line growth in non-ARV segments. - **88% revenue from regulated markets** (U.S., EU, Japan), minimizing exposure to volatile ROW markets. - **Gross margins stable** despite pricing pressures — attributed to process optimization, scale, and backward integration. - Targeted FY26 growth: **20% revenue increase** and **20% EBITDA margin**, supported by high asset turnover (~1.0x). --- ### **Growth Strategy (2025–2030)** #### **1. Capacity Expansion & Capex** - **₹250–280 crore capital expenditure program** underway: - Expansion of existing API capacity (e.g., Ibuprofen, Sitagliptin). - **Backward integration projects** to further secure supply chains. - **Greenfield CDMO site** in Andhra Pradesh. - **₹30 crore allocated for land acquisition** for future greenfield project. - Completed **₹150 crore backward integration project** in FY25 — now boosting margins from Q2 FY26. #### **2. Product Portfolio & Innovation** - Added **20 new APIs since FY22**. - Plans to launch **8–10 new products annually** across high-demand segments (anti-diabetic, anti-epileptic, anti-inflammatory). - Target: **~30 additional DMFs, CEPs, dossiers** in next 2–3 years. #### **3. Expansion into High-Growth Therapeutic Areas** - **Peptide-focused subsidiary (SMS Peptides Pvt. Ltd.)** established. - Dedicated **R&D facility under construction**. - Target: **Commercial operations by FY29**. - Advancing into **complex molecules** and **off-patent chronic therapies** (e.g., GLP-1 analogs via peptides). - Licensed to manufacture **Molnupiravir & Nirmatrelvir** (antivirals) for MPP/WHO markets. #### **4. Market Penetration** - **Ibuprofen: Export-focused (70%)**, with CEP approval enabling European market access. - Europe growth: Strengthened via JV with Chemo; now **leading in anti-diabetic APIs** post-patent expiry. - Expanding client base in **Bangladesh, Indonesia, Brazil, MENA, and U.S. markets**. --- ### **Management & Governance** - **Leadership**: - **Ramesh Babu Potluri** (Chairman & MD): Instrumental in acquiring SMS in 1990; pioneer of low-cost Ibuprofen process; secured early USFDA approval. - **Vamsi Krishna Potluri** (Executive Director): Leads operations; scaled Unit II 2x over 5 years without CAPEX. - **Strong family leadership with deep domain expertise**, aligned incentives, and long-term vision. --- ### **Awards & Recognition** - **“Indian Pharma Bulk Drug Company of the Year”** and **“Best Bulk Drug Export Company of the Year”** (Govt. of India, 2015). - **Indo-US Green Chemistry Network Award** for sustainable manufacturing processes. - Repeated **USFDA, EU-GMP, EDQM, WHO approvals** — testament to quality and compliance.